Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
189
resultados
Última actualización
29/04/2025 [06:51:00]
Resultados 50 a 75 de 189
Resumen de: WO2025085425A1
A non-cationic nanoparticle composition comprising an albumin-coated nanoparticle, which comprises a nucleic acid bound to a polyphenol; a method of preparation; and use thereof in the treatment or inhibition of onset of cancer and other diseases.
Resumen de: WO2025085909A1
Disclosed herein are nanoparticle immunoadjuvant complexes and nucleic acid molecules encoding the same. Also disclosed herein is a method of treating or preventing a disease or disorder associated with an antigen presented on n nanoparticle immunoadjuvant complex in a subject in need thereof, by administering the antigen presenting nanoparticle immunoadjuvant complex, or encoding nucleic acid molecules, to the subject.
Resumen de: WO2025085865A1
Provided herein are co-assembling peptides which may form granules under stimulating conditions. Also provided herein are granules comprising RNA-guided nucleases which are capable of modifying DNA, for example, in the presence of a guide RNA. Further provided herein are methods of making each of the co-assembling peptides and granules thereof.
Resumen de: WO2025085796A1
The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target DLL3 and cells comprising such DLL3-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the DLL3-targeted antigen-recognizing receptors for treatment.
Resumen de: WO2025085507A2
The present invention provides multi-functional (e.g., repelling biofilms, promoting formation of minerals, and having anti-infection properties) compositions and methods of use thereof. In various embodiments, the present invention also provides method for promoting bone growth, promoting cell adhesion, promoting cell expression, promoting anti-infection effect (e.g., promoting anti-bacterial effect, promoting anti-fungal effect, promoting anti-viral effect, etc.), promoting anti-inflammatory effect, preventing or treating diseases or disorders, or any combination thereof in a subject in need thereof.
Resumen de: WO2025085275A1
The present disclosure provides compositions and methods for increasing mitochondrial function or decreasing cellular oxidative stress. The present disclosure further provides nanomaterial structures comprising high atomic vacancy concentrations. Aspects of the disclosure further relate to methods for treating diseases or disorders associated with decreased mitochondrial function or increased cellular oxidative stress.
Resumen de: WO2025084317A1
The purpose of the invention described herein is to provide a compound having a novel chemical structure that is usable for lipid nanoparticles. Disclosed are a compound represented by formula (I) (in the formula, R1 and R2 are each independently a C10-24 chain hydrocarbon group, R3 is a C1-22 chain hydrocarbon group) and lipid nanoparticles containing the compound.
Resumen de: WO2025084854A1
When a biological material sensitive to an external reaction is incorporated during hydrogel production, physical stimulation or chemical stimulation applied in conventional hydrogel production methods requires a sophisticated process and can affect the activity and structure of particles in the hydrogel. On the other hand, a hydrogel using an aqueous-two phase system and a method for producing same provided by the present invention can simultaneously achieve hydrogel formation and the encapsulation of desired nanoparticles in the hydrogel. The present invention has succeeded in simply concentrating desired nanoparticles in a hydrogel with a high yield. In addition, the present invention relates to a hydrogel using an aqueous-two phase system and a method for producing same, wherein concentration and hydrogel formation are simultaneously performed, and thus the time for producing the hydrogel is reduced and the cost is significantly reduced.
Resumen de: WO2025083657A1
The present invention relates to a novel lipid compound for tissue-specific delivery and a lipid nanoparticle (LNP) including same. The lipid nanoparticle includes, as a component, a lipid compound modified such that an active substance therein is selectively delivered into cells of a specific tissue such as lymph nodes, the spleen, the retina, cancer, the brain, the liver, and the like in vivo, thereby preventing side effects and safely exhibiting a desired level of effects. These tissue-specific, non-viral LNP carriers can be effectively utilized for the prevention of infectious diseases and the treatment of rare and intractable (hereditary) diseases (macular degeneration, diabetic retinopathy, hereditary retinal degeneration, cancer, brain diseases, liver diseases, and etc.), where targeted and selective delivery within the body is crucial.
Resumen de: WO2025082397A1
The present application discloses a compound having a structural formula as shown in formula (I), and a salt and isomer thereof. The present application also discloses a nanoparticle composition comprising the compound or the salt or isomer thereof. The nanoparticle of the present application can efficiently deliver an active ingredient into a cell to achieve the purpose of treatment or prevention.
Resumen de: WO2025082447A1
Provided are a nanobody targeting 5T4 and a use thereof. Specifically, provided are an anti-5T4 nanobody, and a long-acting anti-5T4 nanobody formed by linking the anti-5T4 nanobody with an anti-serum-albumin nanobody in tandem. Furthermore, the antibody can be used for preparing an antibody-drug conjugate and constructing a chimeric antigen receptor and an engineered immune cell expressing the chimeric antigen receptor. The antibody, the antibody-drug conjugate, and the engineered immune cell can be used for preparing a drug for treating and/or preventing diseases or disorders associated with 5T4, such as solid tumors and malignant hemopathies.
Resumen de: TW202432572A
The present application relates to the field of biotechnology, specifically to an mRNA vaccine for treating HPV infection related diseases by inducing HPV antigen-specific immune responses.
Resumen de: PH12021500045A1
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The ionizable amine lipids disclosed herein are useful as ionizable lipids in the formulation of lipid nanoparticle-based compositions.
Resumen de: MX2021009485A
Disclosed herein are methods for treating osteoarthritis may be a one-step arthroscopic procedure and may include detaching synovial mesenchymal stem cells (MSCs) from the synovium using a brush device; covering articular cartilage in an affected joint with a scaffold; and placing concentrated MSC exosomes into the affected joint to stimulate differentiation of synovial MSCs into articular cartilage cells.
Resumen de: WO2023245177A2
This disclosure relates to compositions and methods for treating lung disorders, including, for example, Acute Respiratory Distress Syndrome (ARDS), Ventilator-Induced Lung Injury (VILI), Acute lung injury (ALI), and other acute and chronic lung disorders.
Resumen de: WO2023245176A1
This disclosure relates to compositions and methods for treating lung disorders, including, for example, pulmonary fibrosis, and other fibrotic disorders. Thioredoxin domain-containing 5 (TXNDC5) is significantly increased in fibrotic lungs from human PF patients. Therefore, a targeted nanoparticle comprising an inhibitor of TXNDC5 was developed, which may have potential to treat pulmonary fibrosis.
Resumen de: AU2023295550A1
The present disclosure provides a method of enhancing an immune response in a subject in need thereof, including administering an effective amount of an antigen with an immune modulator to the subject, wherein the immune modulator is a quaternary immunomodulatory nanoparticle (QIN). The present disclosure also provides the use of the QIN in the manufacture of a chimeric nanoparticle, a pharmaceutical composition and a medicament for treating a subject suffering from a cancer or virus infection.
Resumen de: CN117567535A
The present application relates to bio-orthogonal compositions. The present disclosure provides bioorthogonal compositions for delivering agents in a subject. The disclosure also provides methods of producing these compositions and methods of using these compositions.
Resumen de: WO2023244803A1
This application relates in part to nanoparticles comprising a tobamovirus and nanoparticles comprising a tobamovirus and beta-cyclodextrin (β-CD or BCD). This application also relates in part to nanoparticles comprising tobamovirus and one or more active ingredients (AIs) that are non-covalently conjugated to the tobamovirus. The application also provides methods of making and methods of using such nanoparticles as well as compositions comprising the disclosed nanoparticles.
Resumen de: MX2025000643A
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
Resumen de: WO2023242843A1
The technology generally concerns selective modulation of only a peripheral CB 1R by using a CB 1R antagonist contained in a peripherally restricted delivery system.
Resumen de: AU2023290692A1
Provided herein include compositions, methods and systems for delivery of CRISPR/Cas-mediated gene editing systems using lipid nanoparticles (LNP) to trabecular meshwork cells. Methods, compositions and systems for treating glaucoma are also provided herein, which involve reducing the expression of myocilin (
Resumen de: AU2023290551A1
The present invention is within the technical field of pain-relief and relates to a pharmaceutical composition comprising at least one anesthetic agent selected from the group consisting of ropivacaine, bupivacaine, etidocaine, levobupivacaine, lidocaine, lignocaine, mepivacaine, articaine, dibucaine, levobupivacaine, prilocaine, benzocaine, chloroprocaine, cocaine, procaine, proparacaine, tetracaine and any pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof; at least one alkanolamine selected from the group consisting of triethanolamine, tripropanolamine and trimethanolamine; water; and optionally a pharmaceutically acceptable diluent, carrier and/or excipient. The present disclosure furthermore relates to the use of the composition for providing pain-relief, a method of treatment, a method of producing said pharmaceutical composition as well as a carbon quantum dot formed from components of the pharmaceutical composition.
Resumen de: AU2023290273A1
Chimeric antigen receptor (CAR)-expressing neutrophils loaded with nanoparticles comprising a drug; and a method of treating cancer or other disorders in a subject comprising administering to the subject a therapeutically effective amount of the CAR-expressing neutrophils.
Nº publicación: PL446441A1 22/04/2025
Solicitante:
CHDE POLSKA SPOLKA AKCYJNA [PL]
CHDE POLSKA SP\u00D3\u0141KA AKCYJNA
Resumen de: WO2025084940A1
The invention relate to a compound of the general formula presented in the description of the invention for use in the treatment or prevention of diseases associated with vascular endothelial dysfunction, wherein it is provided in nanocapsules having a diameter of no more than 1 pm, containing a lipophilic core and a hydrophilic shell, wherein the nanocapsules are intended for oral administration.
BOPI
Sede Electrónica
